Pierre Sayad was appointed Senior Vice President, U.S. Medical Affairs, in 2021.
Pierre brings more than 20 years of pharmaceutical experience to his new role, including numerous leadership positions in the Multiple Myeloma space. Prior to joining Oncopeptides, Pierre was Vice President, Global Medical and Scientific Affairs at Karyopharm Therapeutics, where he led the development of global strategy for scientific communications, Medical Science Liaisons, medical information, operations and patient advocacy. Previously, Pierre served as Senior Vice President at the International Myeloma Foundation and he also led the Medical Strategy and Operations team that supported the development, approval and launch of Kyprolis for relapsed refractory multiple myeloma at Onyx Pharmaceuticals. Pierre began his career at Eli Lilly and Company, where he helped drive the successful launches of the neuroscience blockbusters Zyprexa®, Cymbalta®, and Strattera®.
Pierre holds a B.S. degrees in Molecular Physiology and Psychology, as well as a B.A. in Music, from San Jose State University. He received his M.S degree in Molecular Physiology and Biomedical Sciences from the Loma Linda University School of Medicine. Pierre completed his graduate work in the field of multiple myeloma and holds a PhD in Psychoneuroimmunology (PNI). Starting in the Summer of 2021, Pierre will begin Harvard Business School and has been accepted to the Advanced Management Program.